naa a22 4500 510763855 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1006-4 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1006-4 Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response [Elektronische Daten] [P. Sánchez-Rovira, M. Seguí, A. Llombart, E. Aranda, A. Antón, A. Sánchez, M. Lomas, A. Jaén, M. Fernández, I. Porras, E. Dalmau, S. Morales, J. de la Haba-Rodríguez] Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Methods: Patients with HER-negative operable stage II-III BC ≥2cm were enrolled. Four cycles of AC (A 60mg/m2 and C 600mg/m2, every 3weeks) followed by 4 cycles of BT (B 15mg/kg and T 75mg/m2, every 3weeks), were planned. A core-biopsy was performed for biological markers assessment. Results: Seventy-two women were included. Forty-three (63%) patients were hormone receptor-positive. Sixty-four (89%) completed the planned treatment, and 66 evaluable patients underwent surgery (92%): a pCR was achieved in 16 of them (24, 95% CI 15-36%). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86% (95% CI 76-93%), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials. The Author(s), 2013 Bevacizumab nationallicence Biomarkers nationallicence Breast cancer nationallicence Combined modality therapy nationallicence Neoadjuvant therapy nationallicence Sánchez-Rovira P. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut Seguí M. Medical Oncology, Corporació Sanitària Parc Taulí, Barcelona, Spain aut Llombart A. Medical Oncology, Hospital Universitàri Arnau de Vilanova, Lleida, Spain aut Aranda E. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut Antón A. Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain aut Sánchez A. Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain aut Lomas M. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut Jaén A. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut Fernández M. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut Porras I. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut Dalmau E. Medical Oncology, Corporació Sanitària Parc Taulí, Barcelona, Spain aut Morales S. Medical Oncology, Hospital Universitàri Arnau de Vilanova, Lleida, Spain aut de la Haba-Rodríguez J. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 810-817 1699-048X 15:10<810 2013 15 12094 https://doi.org/10.1007/s12094-013-1006-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1006-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sánchez-Rovira P. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut NATIONALLICENCE 700 1- Seguí M. Medical Oncology, Corporació Sanitària Parc Taulí, Barcelona, Spain aut NATIONALLICENCE 700 1- Llombart A. Medical Oncology, Hospital Universitàri Arnau de Vilanova, Lleida, Spain aut NATIONALLICENCE 700 1- Aranda E. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut NATIONALLICENCE 700 1- Antón A. Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain aut NATIONALLICENCE 700 1- Sánchez A. Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain aut NATIONALLICENCE 700 1- Lomas M. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut NATIONALLICENCE 700 1- Jaén A. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut NATIONALLICENCE 700 1- Fernández M. Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain aut NATIONALLICENCE 700 1- Porras I. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut NATIONALLICENCE 700 1- Dalmau E. Medical Oncology, Corporació Sanitària Parc Taulí, Barcelona, Spain aut NATIONALLICENCE 700 1- Morales S. Medical Oncology, Hospital Universitàri Arnau de Vilanova, Lleida, Spain aut NATIONALLICENCE 700 1- de la Haba-Rodríguez J. Medical Oncology, Hospital Reina Sofía, Córdoba, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 810-817 1699-048X 15:10<810 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer